Interestingly, in the Swiss registry, the patients who experienced adverse events were less often treated with ACE inhibitors/ARBs, the difference that did not reach statistical significance [3/15 (21%) vs. 41/90 (46%); P = 0.09] ( 5 ).
1
0.0900
0.0900